A Phase III Randomized, Double-Blind, Placebo Controlled, Multi-centre Study of Durvalumab Monotherapy or in Combination with Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
AstraZeneca AB
Start Date
December 19, 2019
End Date
December 19, 2024
Administered By
Duke Cancer Institute
Awarded By
AstraZeneca AB
Start Date
December 19, 2019
End Date
December 19, 2024